One of the prime examples is the MediTect IV bag platform. Premixed IV infusion bags provide the ideal grab-and-go solution which may be crucial in emergency situations when every second counts to save a life.
Unlike injectables that require admixing, IV bags are essentially a closed system; this mitigates the risk of exposing patients and medical workers to harmful chemicals, and avoids the risk of human error in drug preparation.
However, conventional IV bags are not suitable for many unstable small molecule and biologic drugs, including those with highly diluted active ingredients such as large-volume parenterals.
ZACROS’s MediTect series is designed to provide an alternative to glass bottles and vials for sensitive drugs.
The IV bags are made from advanced PE or PP blends, and non-interactive (NI) films prevent elution and sorption, resulting in glass-like storage stability.
Suitable for different sterilization methods, MediTect closures can be either rubber infusion caps or "one-touch caps" assuming aseptic filling. For additional barrier properties, overwraps are also possible.
“The growing number of next-generation drugs coming to market has led to increased interest in our technology,” says Pauline Koyanagi, in charge of Global Business Development at ZACROS.
“Many are highly complex and so we work in a collaborative way, developing and testing prototypes together with partners or in our own pilot facilities across a range of parameters from sterilization systems to filling and transport requirements.”
ZACROS’s primary pharmaceutical packaging manufacturing site is ISO 15378 and ISO 13485 certified, and MediTect bags are compliant with USP and JP standards.
The company has sold primary packaging for parenteral drugs to the US and Japan for over 30 years, and some products are DMF registered.